Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

Hypertriglyceridemia has emerged as an independent risk factor for cardiovascular events, despite low-density lipoprotein-cholesterol (LDL-C) well-controlled with statins. We pooled data from the first 12 weeks of six randomized double-blind placebo-controlled studies of pemafibrate in Japan and inv...

Full description

Bibliographic Details
Main Authors: Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hideki Suganami, Shun Ishibashi
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:International Journal of Molecular Sciences
Subjects:
pemafibrate
triglyceride
selective peroxisome proliferator-activated receptor (ppar)α modulator
renal dysfunction
lipoprotein subclass
high-performance liquid chromatography (hplc), concomitant statin
Online Access:https://www.mdpi.com/1422-0067/20/22/5537

Similar Items

Similar Items